Yvonne Greenstreet
CIK 1446125 · View on SEC EDGAR ↗
Insider
First SEC filing: Sept. 14, 2018 · Latest: Sept. 14, 2018
On this page
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 70 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 8, 2022 | PCRX | A | 8,225 | — | — | 8,225 Direct | — | Acquired | (price as of 2026-08-21) |
| June 8, 2022 | PCRX | A | 1,160 | — | — | 13,247 Direct | +9.60% | Acquired | (price as of 2026-08-21) |
| June 9, 2021 | PCRX | A | 1,066 | — | — | 12,087 Direct | +9.67% | Acquired | (price as of 2026-08-21) |
| June 9, 2021 | PCRX | A | 7,626 | — | — | 7,626 Direct | — | Acquired | (price as of 2026-08-21) |
| June 9, 2020 | PCRX | A | 8,027 | — | — | 8,027 Direct | — | Acquired | (price as of 2026-08-21) |
| June 9, 2020 | PCRX | A | 1,260 | — | — | 11,021 Direct | +12.91% | Acquired | (price as of 2026-08-21) |
| June 5, 2019 | PCRX | A | 8,437 | — | — | 8,437 Direct | — | Acquired | (price as of 2026-08-21) |
| June 5, 2019 | PCRX | A | 4,134 | — | — | 9,761 Direct | +73.47% | Acquired | (price as of 2026-08-21) |
| Nov. 14, 2018 | MC | A | 12 | — | — | 1,059 Direct | +1.15% | Acquired | (price as of 2026-08-21) |
| Nov. 14, 2018 | MC | A | 8 | — | — | 706 Direct | +1.15% | Acquired | (price as of 2026-08-21) |
| Nov. 14, 2018 | MC | A | 13 | — | — | 1,157 Direct | +1.14% | Acquired | (price as of 2026-08-21) |
| Sept. 12, 2018 | MC | A | 48 | — | — | 1,396 Direct | +3.56% | Acquired | (price as of 2026-08-21) |
| Sept. 12, 2018 | MC | A | 24 | — | — | 698 Direct | +3.56% | Acquired | (price as of 2026-08-21) |
| Sept. 12, 2018 | MC | A | 39 | — | — | 1,144 Direct | +3.53% | Acquired | (price as of 2026-08-21) |
| July 2, 2018 | MC | A | 1,348 | — | — | 1,348 Direct | — | Acquired | (price as of 2026-08-21) |
| July 2, 2018 | MC | A | 674 | — | — | 674 Direct | — | Acquired | (price as of 2026-08-21) |
| June 13, 2018 | PCRX | A | 4,693 | — | — | 4,693 Direct | — | Acquired | (price as of 2026-08-21) |
| June 13, 2018 | PCRX | A | 782 | — | — | 5,627 Direct | +16.14% | Acquired | (price as of 2026-08-21) |
| May 17, 2018 | MC | A | 2 | — | — | 277 Direct | +0.73% | Acquired | (price as of 2026-08-21) |
| May 17, 2018 | MC | A | 9 | — | — | 1,104 Direct | +0.82% | Acquired | (price as of 2026-08-21) |
| May 17, 2018 | MC | A | 17 | — | — | 2,079 Direct | +0.82% | Acquired | (price as of 2026-08-21) |
| March 7, 2018 | MC | A | 20 | — | — | 548 Direct | +3.79% | Acquired | (price as of 2026-08-21) |
| March 7, 2018 | MC | A | 40 | — | — | 1,095 Direct | +3.79% | Acquired | (price as of 2026-08-21) |
| March 7, 2018 | MC | A | 75 | — | — | 2,063 Direct | +3.77% | Acquired | (price as of 2026-08-21) |
| Dec. 20, 2017 | ALNY | A | 6,250 | — | — | 6,250 Direct | — | Acquired | (price as of 2026-08-21) |
| Nov. 20, 2017 | MC | A | 6 | — | — | 792 Direct | +0.76% | Acquired | (price as of 2026-08-21) |
| Nov. 20, 2017 | MC | A | 8 | — | — | 1,055 Direct | +0.76% | Acquired | (price as of 2026-08-21) |
| Nov. 20, 2017 | MC | A | 16 | — | — | 1,987 Direct | +0.81% | Acquired | (price as of 2026-08-21) |
| Aug. 17, 2017 | MC | A | 10 | — | — | 1,047 Direct | +0.96% | Acquired | (price as of 2026-08-21) |
| Aug. 17, 2017 | MC | A | 10 | — | — | 1,047 Direct | +0.96% | Acquired | (price as of 2026-08-21) |
| Aug. 17, 2017 | MC | A | 19 | — | — | 1,972 Direct | +0.97% | Acquired | (price as of 2026-08-21) |
| July 6, 2017 | MC | A | 49 | — | — | 1,953 Direct | +2.57% | Acquired | (price as of 2026-08-21) |
| July 6, 2017 | MC | A | 15 | — | — | 597 Direct | +2.58% | Acquired | (price as of 2026-08-21) |
| July 1, 2017 | MC | A | 1,037 | — | — | 1,037 Direct | — | Acquired | (price as of 2026-08-21) |
| July 1, 2017 | MC | A | 1,037 | — | — | 1,037 Direct | — | Acquired | (price as of 2026-08-21) |
| June 14, 2017 | PCRX | A | 2,714 | — | — | 2,714 Direct | — | Acquired | (price as of 2026-08-21) |
| June 14, 2017 | PCRX | A | 1,357 | — | — | 4,845 Direct | +38.90% | Acquired | (price as of 2026-08-21) |
| May 24, 2017 | MC | A | 19 | — | — | 1,904 Direct | +1.01% | Acquired | (price as of 2026-08-21) |
| May 24, 2017 | MC | A | 6 | — | — | 582 Direct | +1.04% | Acquired | (price as of 2026-08-21) |
| March 17, 2017 | MC | A | 18 | — | — | 1,885 Direct | +0.96% | Acquired | (price as of 2026-08-21) |
| March 17, 2017 | MC | A | 6 | — | — | 577 Direct | +1.05% | Acquired | (price as of 2026-08-21) |
| Jan. 5, 2017 | MC | A | 67 | — | — | 1,867 Direct | +3.72% | Acquired | (price as of 2026-08-21) |
| Jan. 5, 2017 | MC | A | 20 | — | — | 571 Direct | +3.63% | Acquired | (price as of 2026-08-21) |
| Jan. 5, 2017 | MC | A | 54 | — | — | 1,516 Direct | +3.69% | Acquired | (price as of 2026-08-21) |
| Dec. 20, 2016 | ALNY | A | 25,000 | — | — | 25,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Dec. 7, 2016 | MC | A | 19 | — | — | 1,800 Direct | +1.07% | Acquired | (price as of 2026-08-21) |
| Dec. 7, 2016 | MC | A | 6 | — | — | 551 Direct | +1.10% | Acquired | (price as of 2026-08-21) |
| Dec. 7, 2016 | MC | A | 15 | — | — | 1,462 Direct | +1.04% | Acquired | (price as of 2026-08-21) |
| Sept. 6, 2016 | MC | A | 22 | — | — | 1,781 Direct | +1.25% | Acquired | (price as of 2026-08-21) |
| Sept. 6, 2016 | MC | A | 7 | — | — | 545 Direct | +1.30% | Acquired | (price as of 2026-08-21) |
| Sept. 6, 2016 | MC | A | 18 | — | — | 1,446 Direct | +1.26% | Acquired | (price as of 2026-08-21) |
| July 1, 2016 | MC | A | 1,759 | — | — | 1,759 Direct | — | Acquired | (price as of 2026-08-21) |
| June 15, 2016 | PCRX | A | 2,975 | — | — | 2,975 Direct | — | Acquired | (price as of 2026-08-21) |
| June 15, 2016 | PCRX | A | 1,488 | — | — | 3,488 Direct | +74.40% | Acquired | (price as of 2026-08-21) |
| June 3, 2016 | MC | A | 6 | — | — | 538 Direct | +1.13% | Acquired | (price as of 2026-08-21) |
| June 3, 2016 | MC | A | 16 | — | — | 1,428 Direct | +1.13% | Acquired | (price as of 2026-08-21) |
| March 4, 2016 | MC | A | 21 | — | — | 532 Direct | +4.11% | Acquired | (price as of 2026-08-21) |
| March 4, 2016 | MC | A | 57 | — | — | 1,413 Direct | +4.20% | Acquired | (price as of 2026-08-21) |
| Dec. 8, 2015 | MC | A | 5 | — | — | 511 Direct | +0.99% | Acquired | (price as of 2026-08-21) |
| Dec. 8, 2015 | MC | A | 14 | — | — | 1,356 Direct | +1.04% | Acquired | (price as of 2026-08-21) |
| Sept. 8, 2015 | MC | A | 6 | — | — | 506 Direct | +1.20% | Acquired | (price as of 2026-08-21) |
| Sept. 8, 2015 | MC | A | 15 | — | — | 1,342 Direct | +1.13% | Acquired | (price as of 2026-08-21) |
| July 10, 2015 | MC | A | 500 | — | — | 500 Direct | — | Acquired | (price as of 2026-08-21) |
| June 9, 2015 | MC | A | 9 | — | — | 1,327 Direct | +0.68% | Acquired | (price as of 2026-08-21) |
| June 3, 2015 | PCRX | A | 4,000 | — | — | 4,000 Direct | — | Acquired | (price as of 2026-08-21) |
| June 3, 2015 | PCRX | A | 2,000 | — | — | 2,000 Direct | — | Acquired | (price as of 2026-08-21) |
| March 6, 2015 | MC | A | 8 | — | — | 1,318 Direct | +0.61% | Acquired | (price as of 2026-08-21) |
| Feb. 19, 2015 | MC | A | 1,310 | — | — | 1,310 Direct | — | Acquired | (price as of 2026-08-21) |
| June 3, 2014 | PCRX | A | 8,000 | — | — | 8,000 Direct | — | Acquired | (price as of 2026-08-21) |
| March 4, 2014 | PCRX | A | 15,000 | — | — | 15,000 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (8,225) | $59.39 | June 8, 2032 | 8,225 | Acquired |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock (7,626) | $60.96 | June 9, 2031 | 7,626 | Acquired |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (8,027) | $47.65 | June 9, 2030 | 8,027 | Acquired |
| June 5, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (8,437) | $43.54 | June 5, 2029 | 8,437 | Acquired |
| June 13, 2018 | PCRX | Stock Option (Right to Buy) | Common Stock (4,693) | $38.35 | June 13, 2028 | 4,693 | Acquired |
| Dec. 20, 2017 | ALNY | Performance Stock Option 2016 (right to buy) | Common Stock (6,250) | $42.22 | Dec. 20, 2026 | 6,250 | Acquired |
| June 14, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (2,714) | $44.20 | June 14, 2027 | 2,714 | Acquired |
| Dec. 20, 2016 | ALNY | Stock Option (right to buy) | Common Stock (25,000) | $42.22 | Dec. 20, 2026 | 25,000 | Acquired |
| June 15, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock (2,975) | $40.34 | June 15, 2026 | 2,975 | Acquired |
| June 3, 2015 | PCRX | Stock Option (Right to Buy) | Common Stock (4,000) | $79.43 | June 3, 2025 | 4,000 | Acquired |
| June 3, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock (8,000) | $81.00 | June 3, 2024 | 8,000 | Acquired |
| March 4, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock (15,000) | $80.43 | March 3, 2024 | 15,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
ALNY
PEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $1,404,200 | — | — | — | $3,562,500 | — | $25,020 | $14,867,600 |
| 2024 | $1,253,400 | — | — | — | $2,975,400 | — | $24,770 | $11,492,970 |
| 2023 | $975,800 | — | — | $3,369,000 | $1,155,000 | — | $20,720 | $8,895,670 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.